| Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis EA Kendall, MO Fofana, DW Dowdy The Lancet Respiratory Medicine 3 (12), 963-972, 2015 | 263 | 2015 |
| When to start antiretroviral therapy in resource-limited settings RP Walensky, LL Wolf, R Wood, MO Fofana, KA Freedberg, NA Martinson, ... Annals of internal medicine 151 (3), 157-166, 2009 | 173 | 2009 |
| Scaling up antiretroviral therapy in South Africa: the impact of speed on survival RP Walensky, R Wood, MC Weinstein, NA Martinson, E Losina, ... The Journal of infectious diseases 197 (9), 1324-1332, 2008 | 96 | 2008 |
| The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa RP Walensky, R Wood, MO Fofana, NA Martinson, E Losina, MD April, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (1), 26-35, 2011 | 91 | 2011 |
| Decolonising global health in the time of COVID-19 MO Fofana Global Public Health 16 (8-9), 1155-1166, 2021 | 66 | 2021 |
| The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis GM Knight, C Colijn, S Shrestha, M Fofana, F Cobelens, RG White, ... Clinical Infectious Diseases 61 (suppl_3), S147-S154, 2015 | 62 | 2015 |
| Willingness to get the COVID-19 vaccine among residents of slum settlements JP Aguilar Ticona, N Nery Jr, R Victoriano, MO Fofana, GS Ribeiro, ... Vaccines 9 (9), 951, 2021 | 40 | 2021 |
| Development of global health education at Johns Hopkins University School of Medicine: a student-driven initiative D Moran, J Edwardson, CN Cuneo, S Tackett, J Aluri, A Kironji, J Cox, ... Medical education online 20 (1), 28632, 2015 | 34 | 2015 |
| Cost-effectiveness of novel first-line treatment regimens for tuberculosis JP Owens, MO Fofana, DW Dowdy The International journal of tuberculosis and lung disease 17 (5), 590-596, 2013 | 30 | 2013 |
| A multistrain mathematical model to investigate the role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis MO Fofana, S Shrestha, GM Knight, T Cohen, RG White, F Cobelens, ... Antimicrobial agents and chemotherapy 61 (3), 10.1128/aac. 00498-16, 2017 | 27 | 2017 |
| Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis MO Fofana, GM Knight, GB Gomez, RG White, DW Dowdy PloS one 9 (5), e96389, 2014 | 27 | 2014 |
| Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis S Shrestha, GM Knight, M Fofana, T Cohen, RG White, F Cobelens, ... Open forum infectious diseases 1 (2), ofu073, 2014 | 24 | 2014 |
| Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: a cross-sectional survey MO Fofana, N Nery Jr, JP Aguilar Ticona, EMM de Andrade Belitardo, ... PLoS Medicine 19 (9), e1004093, 2022 | 16 | 2022 |
| Effectiveness of primary and booster COVID-19 mRNA vaccination against Omicron variant SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection ML Lind, AJ Robertson, J Silva, F Warner, AC Coppi, N Price, C Duckwall, ... | 16 | 2022 |
| The spectre of race in American medicine MO Fofana Medical Humanities 39 (2), 137-141, 2013 | 14 | 2013 |
| Time and time again: the reincarnations of coerced sterilisation MO Fofana Journal of Medical Ethics 48 (11), 805-809, 2022 | 13 | 2022 |
| Racial discrimination from patients: institutional strategies to establish respectful emergency department environments AN Chary, MO Fofana, HS Kohli Western Journal of Emergency Medicine 22 (4), 898, 2021 | 9 | 2021 |
| Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis Lancet Respir Med, 3 (2015) EA Kendall, MO Fofana, DW Dowdy View PDF View article View in Scopus, 963-972, 0 | 9 | |
| Reply to Anthony et al.,“Protecting pyrazinamide, a priority for improving outcomes in multidrug-resistant tuberculosis treatment” MO Fofana, DW Dowdy Antimicrobial agents and chemotherapy 61 (6), 10.1128/aac. 00427-17, 2017 | 7 | 2017 |
| Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA. 1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative … ML Lind, AJ Robertson, J Silva, F Warner, AC Coppi, N Price, C Duckwall, ... PLoS medicine 19 (12), e1004136, 2022 | 5 | 2022 |
